Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists demonstrate consistent risk reductions for mortality, myocardial infarction, stroke, heart failure, and renal outcomes, irrespective of their effects on glycemia
The real question isn't what happens at week 68 or week 80 it's what happens at year 3, year 5, and beyond
Instead, consider using the single puncture threading technique or the multiple puncture technique
Before beginning any supplementation regimen, particularly if you have existing health conditions or take medications, consulting with a healthcare provider is always recommended to ensure safety and appropriateness for your individual situation.
Transitioning from Insulin to GLP-1 Agonists Transitioning from insulin to GLP-1 agonist medications presents several challenges